On May 9, 2024, eFFECTOR Therapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13D/A filing with the U.S. Securities and Exchange Commission (SEC) by The Carlyle Group and associated entities. The filing, which is an amendment to a previous Schedule 13D, reports that The Carlyle Group and several related entities collectively own 193,195 shares of eFFECTOR Therapeutics' common stock, representing 4.1% of the company. This ownership stake is a result of a 1-for-25 reverse stock split effected by eFFECTOR Therapeutics on January 9, 2024. The Carlyle Group Inc. is the ultimate parent entity in a chain of ownership that includes Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L...Show More

On May 9, 2024, eFFECTOR Therapeutics, Inc., a biopharmaceutical company, was the subject of a Schedule 13D/A filing with the U.S. Securities and Exchange Commission (SEC) by The Carlyle Group and associated entities. The filing, which is an amendment to a previous Schedule 13D, reports that The Carlyle Group and several related entities collectively own 193,195 shares of eFFECTOR Therapeutics' common stock, representing 4.1% of the company. This ownership stake is a result of a 1-for-25 reverse stock split effected by eFFECTOR Therapeutics on January 9, 2024. The Carlyle Group Inc. is the ultimate parent entity in a chain of ownership that includes Carlyle Holdings I GP Inc., Carlyle Holdings I GP Sub L.L.C., Carlyle Holdings I L.P., CG Subsidiary Holdings L.L.C., TC Group, L.L.C., Carlyle Investment Management L.L.C., Carlyle Genesis UK LLC, Abingworth LLP, and Abingworth Bioventures VI LP. The filing also indicates that as of May 9, 2024, the reporting entities ceased to be beneficial owners of more than five percent of the outstanding shares of eFFECTOR Therapeutics' common stock. No transactions in the common stock were reported by the entities in the 60 days prior to the filing.